ClinicalTrials.gg
RecruitingNCT02720679Updated Jun 9, 2026

Investigation of the Genetics of Hematologic Diseases

An observational study in Bone Marrow Failure Syndromes, Erythrocyte Disorder and Leukocyte Disorder, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by St. Jude Children's Research Hospital · Observational

How we know

From the registry’s dates

  • Started Jun 2016; still recruiting 10 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,716
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Bone Marrow Failure Disorders with a site in United States — 21 open to participants now, 29 under way, none of them phase 3. Bone Marrow Failure Disorders · United States.

Planned enrollment
2nd of 10
1,716 · median 325
Started
2016
with 2 others
Observational
10 of 67
5 open now
Primary completion
2040-07
later than 27 of 28 live
Registered
31st of 67
by date
Lead sponsor
3 of 67
St. Jude Children's Research Hospital

Among the 67 studies in Bone Marrow Failure Disorders with a site in United States, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2016, is one of 10 observational ones, reaches primary completion later than 27 of the 28 other live ones, and was the 31st registered.

Bone Marrow Failure Disorders

91 studies on the registry are indexed under Bone Marrow Failure Disorders; 29 are open to participants now.

Browse Bone Marrow Failure Disorders studies →

Open to participants now

21 of the 67 studies in Bone Marrow Failure Disorders with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Bone Marrow Failure Disorders studies recruiting now, 9 (39%) set no upper age limit and 12 (52%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Bone Marrow Failure Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to collect and store samples and health information for current and future research to learn more about the causes and treatment of blood diseases. This is not a therapeutic or diagnostic protocol for clinical purposes. Blood, bone marrow, hair follicles, nail clippings, urine, saliva and buccal swabs, left over tissue, as well as health information will be used to study and learn about blood diseases by using genetic and/or genomic research. In general, genetic research studies specific genes of an individual; genomic research studies the complete genetic makeup of an individual.

It is not known why many people have blood diseases, because not all genes causing these diseases have been found. It is also not known why some people with the same disease are sicker than others, but this may be related to their genes. By studying the genomes in individuals with blood diseases and their family members, the investigators hope to learn more about how diseases develop and respond to treatment which may provide new and better ways to diagnose and treat blood diseases.

Primary Objective:

  • Establish a repository of DNA and cryopreserved blood cells with linked clinical information from individuals with non-malignant blood diseases and biologically-related family members, in conjunction with the existing St. Jude biorepository, to conduct genomic and functional studies to facilitate secondary objectives.

Secondary Objectives:

  • Utilize next generation genomic sequencing technologies to Identify novel genetic alternations that associate with disease status in individuals with unexplained non-malignant blood diseases.
  • Use genomic approaches to identify modifier genes in individuals with defined monogenic non-malignant blood diseases.
  • Use genomic approaches to identify genetic variants associated with treatment outcomes and toxicities for individuals with non-malignant blood disease.
  • Use single cell genomics, transcriptomics, proteomics and metabolomics to investigate biomarkers for disease progression, sickle cell disease (SCD) pain events and the long-term cellular and molecular effects of hydroxyurea therapy.
  • Using longitudinal assessment of clinical and genetic, study the long-term outcomes and evolving genetic changes in non-malignant blood diseases.

Exploratory Objectives

  • Determine whether analysis of select patient-derived bone marrow hematopoietic progenitor/stem (HSPC) cells or induced pluripotent stem (iPS) cells can recapitulate genotype-phenotype relationships and provide insight into disease mechanisms.
  • Determine whether analysis of circulating mature blood cells and their progenitors from selected patients with suspected or proven genetic hematological disorders can recapitulate genotype-phenotype relationships and provide insight into disease mechanisms.
Read the detailed description

Participants will be individuals (proband) receiving therapy or expert consultation regarding a non-malignant hematologic disorder. We propose to use genomics, transcriptomics, proteomics and metabolomic analysis coupled with family linkage studies to identify causal mutations in individuals with undefined hematologic disorders and to characterize genetic modifiers of defined monogenic blood diseases.

A detailed medical history will be obtained, including demographic information for each proband. For each identified biologically related family member, a medical history questionnaire will be obtained. The family history and pedigree will be reviewed in conjunction with a geneticist/genetic counselor. The implications of genetic testing will be explained. If participants consent for future contact, this will take place annually for updates on medical and family history.

All probands will provide peripheral blood samples, and probands who are undergoing a bone marrow aspirate/biopsy for clinical purposes will provide additional aspirates. Biological family members will provide peripheral blood samples as a source for DNA.

03

Conditions studied

  • Bone Marrow Failure Syndromes
  • Erythrocyte Disorder
  • Leukocyte Disorder
  • Hemostasis
  • Blood Coagulation Disorder
  • Sickle Cell Disease
  • Dyskeratosis Congenita
  • Diamond-Blackfan Anemia
  • Congenital Thrombocytopenia
  • Severe Congenital Neutropenia
  • Fanconi Anemia
  • Myelodysplastic Syndromes
  • Myeloproliferative Diseases

Keywords

  • Genetics
  • Whole genome sequencing
  • Pediatrics and hematology
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be (1) individuals with a non-malignant hematologic disorder confirmed or suspected to have a genetic basis, and (2) affected and unaffected family members of those individuals who are willing to provide clinical data and undergo genetic testing.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An individual (proband) receiving therapy or expert consultation regarding a non-malignant hematologic disorder, MDS or MPN.
  • A biologically-related individual to the identified proband to include: first, second or third degree relatives.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,716 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Study Participants

    Participants will be (1) individuals with a non-malignant hematologic disorder confirmed or suspected to have a genetic basis, and (2) affected and unaffected family members of those individuals who are willing to provide clinical data and undergo genetic testing.

06

What researchers measure

Primary outcomes

  1. Percent of participants who agree to participate

    It is estimated that approximately 30% of participants (proband) approached for this study will agree to participate and that each proband will have approximately five biologically-related family members who agree to participate.

    Time frame: Day 1, at enrollment

Secondary outcomes

  1. Number by type of inherited genetic aberrations associated with hematologic disorders

    Germ-line DNA samples from study participants will be extracted and analyzed in order to identify inherited genetic aberrations associated with hematologic disorders. Specific modalities of genomic testing will be case specific. Relevant tests may involve SNP arrays to assess copy number variation, WGS, WES, targeted sequencing of specific candidate genes, DNA sequencing, RNA-sequencing, X-chromosome inactivation studies, ChIP sequencing and/or other tests. Genetic linkage analyses may be performed using a variety of technologies including high-density SNP arrays, WGS and specific analysis of selected target genes in validation studies.

    Time frame: Blood drawn at study entry, yearly and as needed until July 2050; and/or bone marrow aspirate at study entry, yearly and as needed until July 2050

  2. Number by type of modifier genes

    Investigators seek to identify modifier genes in individuals in the study population. Methods of analysis will be similar to those for Outcome Measure #2.

    Time frame: Blood drawn at study entry, yearly, and as needed until July 2050; and/or bone marrow aspirate at study entry, yearly and as needed until July 2050.

  3. Number by type of genetic variants

    Investigators seek to identify genetic variants associated with treatment outcomes and toxicities in the study population. Methods of analysis will be similar to those for Outcome Measure #2.

    Time frame: Blood drawn at study entry, yearly and as needed until July 2050; and/or bone marrow aspirate at study entry, yearly and as needed until July 2050.

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2016 (actual). Primary completion is estimated for Jul 2040, 289 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2016
First posted
Mar 28, 2016
StartActual
Jun 17, 2016
Primary completionEst.
Jul 2040
CompletionEst.
Jul 2050
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02720679
Collaborators
Boston Children's Hospital, University of Memphis, Monroe Carell Jr. Children's Hospital at Vanderbilt, Baylor College of Medicine, Children's Hospital of Philadelphia, Dana-Farber Cancer Institute
Responsible party
Sponsor
First posted
Mar 28, 2016
Start date
Jun 17, 2016
Primary completion
Jul 2040 (estimated)
Completion
Jul 2050 (estimated)
Last update
Jun 9, 2026

Study contacts

Marcin Wlodarski, MD, PhD
Contact
referralinfo@stjude.org
888-226-4343
Marcin Wlodarski, MD, PhD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion